NOVARTIND vs QMSMEDI: Stock Comparison
NOVARTIND shows a lower P/E, a higher ROE and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
NOVARTIND leads 11; QMSMEDI leads 1 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | NOVARTIND | QMSMEDI |
|---|---|---|
| Sector | Healthcare | — |
| Industry | Pharmaceuticals | — |
Price
| Metric | NOVARTIND | QMSMEDI |
|---|---|---|
| Live Price | ₹1,722.4 | ₹138.13 |
| Day Change | 0.27% | 4.71% |
| Volume | 27,268 | 1.25 L |
| 52-Week High | ₹2,588.8 | ₹140 |
| 52-Week Low | ₹950 | ₹98.05 |
| Distance from 52W High | -33.47% | -1.34% |
Valuation
| Metric | NOVARTIND | QMSMEDI |
|---|---|---|
| Market Cap | ₹4,246 Cr | — |
| P/E Ratio | 0x | 12.43x |
| P/B Ratio | 0x | 1.95x |
| EPS | ₹13.05 | ₹1.89 |
| Book Value | ₹331.23 | ₹58.93 |
| Dividend Yield | 0% | 0% |
Growth
| Metric | NOVARTIND | QMSMEDI |
|---|---|---|
| Revenue Growth (TTM YoY) | 8% | 0% |
| EPS Growth (TTM YoY) | -13.8% | 0% |
| Qtr Sales Growth | 14.64% | 0% |
| Qtr Profit Growth | 27.56% | 0% |
Profitability & Leverage
| Metric | NOVARTIND | QMSMEDI |
|---|---|---|
| ROE | 11.39% | 10.46% |
| ROCE | 12.29% | 8.9% |
| Net Margin | 26.3% | 0% |
| Operating Margin | 36.95% | 13.3% |
| Debt to Equity | 0x | 0.65x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | NOVARTIND | QMSMEDI |
|---|---|---|
| Promoter Holding | 0% | 68.11% |
| FII Holding | 0.16%▼ 0.01 pp | 0.41%▲ 0.41 pp |
| DII Holding | 1.36%▲ 0.83 pp | 1.3%▼ 0.29 pp |
| Public Holding | 27.8%▼ 0.81 pp | 30.17%▼ 0.13 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: NOVARTIND and QMSMEDI.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.